Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer

Authors: Theresa L Wellman, Midori Eckenstein, Cheung Wong, Mercedes Rincon, Takamaru Ashikaga, Sharon L Mount, Christopher S Francklyn, Karen M Lounsbury

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Ovarian tumors create a dynamic microenvironment that promotes angiogenesis and reduces immune responses. Our research has revealed that threonyl-tRNA synthetase (TARS) has an extracellular angiogenic activity separate from its function in protein synthesis. The objective of this study was to test the hypothesis that TARS expression in clinical samples correlates with angiogenic markers and ovarian cancer progression.

Methods

Protein and mRNA databases were explored to correlate TARS expression with ovarian cancer. Serial sections of paraffin embedded ovarian tissues from 70 patients diagnosed with epithelial ovarian cancer and 12 control patients were assessed for expression of TARS, vascular endothelial growth factor (VEGF) and PECAM using immunohistochemistry. TARS secretion from SK-OV-3 human ovarian cancer cells was measured. Serum samples from 31 tissue-matched patients were analyzed by ELISA for TARS, CA-125, and tumor necrosis factor-α (TNF-α).

Results

There was a strong association between the tumor expression of TARS and advancing stage of epithelial ovarian cancer (p < 0.001). TARS expression and localization were also correlated with VEGF (p < 0.001). A significant proportion of samples included heavy TARS staining of infiltrating leukocytes which also correlated with stage (p = 0.017). TARS was secreted by ovarian cancer cells, and patient serum TARS was related to tumor TARS and angiogenic markers, but did not achieve significance with respect to stage. Multivariate Cox proportional hazard models revealed a surprising inverse relationship between TARS expression and mortality risk in late stage disease (p = 0.062).

Conclusions

TARS expression is increased in epithelial ovarian cancer and correlates with markers of angiogenic progression. These findings and the association of TARS with disease survival provide clinical validation that TARS is associated with angiogenesis in ovarian cancer. These results encourage further study of TARS as a regulator of the tumor microenvironment and possible target for diagnosis and/or treatment in ovarian cancer.
Appendix
Available only for authorised users
Literature
1.
Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR: Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev. 2011, 11 (10): 719-725. 10.1038/nrc3144.CrossRef
2.
Mucaj V, Shay JE, Simon MC: Effects of hypoxia and HIFs on cancer metabolism. Int J Hematol. 2012, 95 (5): 464-470. 10.1007/s12185-012-1070-5.CrossRefPubMed
3.
4.
Shield K, Ackland ML, Ahmed N, Rice GE: Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol. 2009, 113 (1): 143-148. 10.1016/j.ygyno.2008.11.032.CrossRefPubMed
5.
Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B, Vergote I: HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011, 104 (5): 863-870. 10.1038/sj.bjc.6606092.CrossRefPubMedPubMedCentral
6.
Wong C, Wellman TL, Lounsbury KM: VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol. 2003, 91 (3): 513-517. 10.1016/j.ygyno.2003.08.022.CrossRefPubMed
7.
Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC: Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol. 2007, 106 (2): 311-317. 10.1016/j.ygyno.2007.03.041.CrossRefPubMedPubMedCentral
8.
Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR, Australian Ovarian Cancer Study G: A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012, 72 (1): 66-75. 10.1158/0008-5472.CAN-11-2178.CrossRefPubMed
9.
Funahashi Y, Wakabayashi T, Semba T, Sonoda J, Kitoh K, Yoshimatsu K: Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor. Oncol Res. 1999, 11 (7): 319-329.PubMed
10.
Howard OMZ, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, Casciola-Rosen L, Härtlein M, Kron M, Yang D, Yiadom K, Dwivedi S, Plotz PH, Oppenheim JJ: Histidyl-tRNA Synthetase and Asparaginyl-tRNA Synthetase, Autoantigens in Myositis, Activate Chemokine Receptors on T Lymphocytes and Immature Dendritic Cells. J Exp Med. 2002, 196 (6): 781-791. 10.1084/jem.20020186.CrossRefPubMedPubMedCentral
11.
Sigurgeirsson B, Lindelof B, Edhag O, Allander E: Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992, 326 (6): 363-367. 10.1056/NEJM199202063260602.CrossRefPubMed
12.
Suber TL, Casciola-Rosen L, Rosen A: Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol. 2008, 4 (4): 201-209. 10.1038/ncprheum0760.CrossRefPubMed
13.
Williams TF, Mirando AC, Wilkinson B, Francklyn CS, Lounsbury KM: Secreted Threonyl-tRNA synthetase stimulates endothelial cell migration and angiogenesis. Nat Sci Reports. 2013, 3: 1317-
14.
Barrett T, Edgar R: Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Meth in Enz. 2006, 411: 352-369.CrossRef
15.
Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Bjorling L, Ponten F: Towards a knowledge-based Human Protein Atlas. Nat Biotech. 2010, 28 (12): 1248-1250. 10.1038/nbt1210-1248.CrossRef
16.
Cassavaugh JM, Hale SA, Wellman TL, Howe AK, Wong C, Lounsbury KM: Negative regulation of HIF-1α by an FBW7-mediated degradation pathway during hypoxia. J Cell Biochem. 2011, 112 (12): 3882-3890. 10.1002/jcb.23321.CrossRefPubMedPubMedCentral
17.
Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, Morin PJ: Large-Scale Serial Analysis of Gene Expression Reveals Genes Differentially Expressed in Ovarian Cancer. Cancer Res. 2000, 60 (22): 6281-6287.PubMed
18.
Moreno CS, Matyunina L, Dickerson EB, Schubert N, Bowen NJ, Logani S, Benigno BB, McDonald JF: Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PloS one. 2007, 2 (5): e441-10.1371/journal.pone.0000441.CrossRefPubMedPubMedCentral
19.
Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R: Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 2013, 24 (6): 751-765. 10.1016/j.ccr.2013.10.013.CrossRefPubMedPubMedCentral
20.
Erickson BK, Conner MG, Landen CN: The role of the fallopian tube in the origin of ovarian cancer. Am J of Obst and Gynecol. 2013, 209 (5): 409-414. 10.1016/j.ajog.2013.04.019.CrossRef
21.
Suh KS, Park SW, Castro A, Patel H, Blake P, Liang M, Goy A: Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expt Rev of Mol Diag. 2010, 10 (8): 1069-1083. 10.1586/erm.10.87.CrossRef
22.
Michalaki V, Syrigos K, Charles P, Waxman J: Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004, 90 (12): 2312-2316.PubMedPubMedCentral
23.
Yadavalli SS, Ibba M: Quality control in aminoacyl-tRNA synthesis its role in translational fidelity. Adv Protein Chem Struc Biol. 2012, 86: 1-43.CrossRef
24.
Sampath P, Mazumder B, Seshadri V, Gerber CA, Chavatte L, Kinter M, Ting SM, Dignam JD, Kim S, Driscoll DM, Fox PL: Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation. Cell. 2004, 119 (2): 195-208. 10.1016/j.cell.2004.09.030.CrossRefPubMed
25.
Park SG, Ewalt KL, Kim S: Functional expansion of aminoacyl-tRNA synthetases and their interacting factors: new perspectives on housekeepers. Trends Biochem Sci. 2005, 30 (10): 569-574. 10.1016/j.tibs.2005.08.004.CrossRefPubMed
26.
Greenberg Y, King M, Kiosses WB, Ewalt K, Yang X, Schimmel P, Reader JS, Tzima E: The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells. Faseb J. 2008, 22 (5): 1597-1605.CrossRefPubMed
27.
Wakasugi K, Slike BM, Hood J, Otani A, Ewalt KL, Friedlander M, Cheresh DA, Schimmel P: A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. PNAS. 2002, 99 (1): 173-177. 10.1073/pnas.012602099.CrossRefPubMedPubMedCentral
28.
Kim S, You S, Hwang D: Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer. 2011, 11 (10): 708-718. 10.1038/nrc3124.CrossRefPubMed
29.
Fukui H, Hanaoka R, Kawahara A: Noncanonical Activity of Seryl-tRNA Synthetase Is Involved in Vascular Development. Circ Res. 2009, 104 (11): 1253-1259. 10.1161/CIRCRESAHA.108.191189.CrossRefPubMed
30.
Park MC, Kang T, Jin D, Han JM, Kim SB, Park YJ, Cho K, Park YW, Guo M, He W, Yang X-L, Schimmel P, Kim S: Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis. PNAS. 2012, 109 (11): E640-E647. 10.1073/pnas.1200194109.CrossRefPubMedPubMedCentral
31.
Cassavaugh J, Lounsbury KM: Hypoxia-mediated biological control. J Cell Biochem. 2011, 112 (3): 735-744. 10.1002/jcb.22956.CrossRefPubMed
32.
Schmitt J, Matei D: Targeting angiogenesis in ovarian cancer. Cancer Treat Rev. 2012, 38 (4): 272-283. 10.1016/j.ctrv.2011.06.004.CrossRefPubMed
33.
Mathivanan S, Fahner CJ, Reid GE, Simpson RJ: ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucl Acids Res. 2012, 40 (D1): D1241-D1244. 10.1093/nar/gkr828.CrossRefPubMed
34.
Liang B, Peng P, Chen S, Li L, Zhang M, Cao D, Yang J, Li H, Gui T, Li X, Shen K: Characterization and proteomic analysis of ovarian cancer-derived exosomes. J Proteom. 2013, 80: 171-182.CrossRef
35.
Leclerc P, Jibard N, Meng X, Schweizer-Groyer G, Fortin D, Rajkowski K, Kang K, Catelli MG, Baulieu EE, Cadepond F: Quantification of the nucleocytoplasmic distribution of wild type and modified proteins using confocal microscopy: interaction between 90-kDa heat shock protein (Hsp90 alpha) and glucocorticosteroid receptor (GR). Exp Cell Res. 1998, 242 (1): 255-264. 10.1006/excr.1998.4117.CrossRefPubMed
36.
Hamaguchi E, Takamura T, Shimizu A, Nagai Y: Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. JPET. 2003, 307 (3): 987-994. 10.1124/jpet.103.054346.CrossRef
37.
Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, el Fattah MA, Kadmon D, Thompson TC: Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res. 2008, 68 (3): 731-739. 10.1158/0008-5472.CAN-07-2668.CrossRefPubMed
38.
Buschow SI, van Balkom BW, Aalberts M, Heck AJ, Wauben M, Stoorvogel W: MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis. Immunol Cell Biol. 2010, 88 (8): 851-856. 10.1038/icb.2010.64.CrossRefPubMed
39.
Townsend KN, Spowart JE, Huwait H, Eshragh S, West NR, Elrick MA, Kalloger SE, Anglesio M, Watson PH, Huntsman DG, Lum JJ: Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma. PloS one. 2013, 8 (12): e82406-10.1371/journal.pone.0082406.CrossRefPubMedPubMedCentral
Metadata
Title
Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer
Authors
Theresa L Wellman
Midori Eckenstein
Cheung Wong
Mercedes Rincon
Takamaru Ashikaga
Sharon L Mount
Christopher S Francklyn
Karen M Lounsbury
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-620

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

MiR-205 inhibits cell apoptosis by targeting phosphatase and tensin homolog deleted on chromosome ten in endometrial cancer ishikawa cells

Research article

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

Research article

A germline mutation in the BRCA13’UTR predicts Stage IV breast cancer

Research article

Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells

Research article

Distress, anxiety and depression in patients with brain metastases before and after radiotherapy

Research article

Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits